Phoenix Molecular Designs has dosed the first patient in Dauntless-1, a Phase 2 trial evaluating PMD-026, a first-in-class pan-RSK inhibitor, in combination with fulvestrant for HR+/HER2-/RSK2-high metastatic breast cancer.
Researchers identified that inhibiting RSK1 reduces inflammation and halts the progression of myeloproliferative neoplasms (MPNs) and aggressive acute myeloid leukemia (AML).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.